Prospects of Disease-Modifying Osteoarthritis Drugs

IF 2.6 4区医学 Q2 RHEUMATOLOGY

Rheumatic Disease Clinics of North America Pub Date : 2024-06-26 DOI:10.1016/j.rdc.2024.03.003

Win Min Oo MD, PhD

引用次数: 0

查看原文本刊更多论文

疾病修饰性骨关节炎药物的前景。

骨关节炎（OA）造成了巨大的疾病负担，2020年全球发病率将接近23%，而由于缺乏改变疾病的药物（DMOADs），适当的治疗需求尚未得到满足。作者根据炎症驱动型、骨驱动型和软骨驱动型的关键 OA 发病机制，回顾了药物开发管线 2/3 期临床试验中活跃的 DMOAD 候选药物的前景。该报告从研究问题的提出（即 PICO 方法）角度阐述了面临的挑战和可能的研究机会：（1）人群；（2）干预措施；（3）对比或安慰剂；（4）结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatic Disease Clinics of North America 医学-风湿病学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Rheumatic Disease Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Each issue (February, May, August, and November) focuses on a single topic in rheumatology and is presented under the direction of an experienced editor. Topics include osteoarthritis, rheumatoid arthritis, crystal diseases, MSK exam, disorders of the bone, immunodeficiency states, lupus, neuromuscular disease, pain disorders, scleroderma, vasculitis, pediatrics, therapeutics, treatment guidelines, and treatment modalities.